A TROP2-targeting aptamer enables selective drug delivery and potent antitumor activity in pancreatic cancer
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
These findings provide preclinical proof-of-concept for T17-M as an alternative TROP2-targeted drug-delivery strategy for PDAC.
Appeared: Friday, November 13. Science Advances. Peer-reviewed journal.